{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T05:04:17Z","timestamp":1766466257936},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s13300-021-01168-x","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T21:11:53Z","timestamp":1634159513000},"page":"3025-3035","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Are the Protean Effects of Pentoxifylline in the Therapy of Diabetes and Its Complications Still Relevant?"],"prefix":"10.1007","volume":"12","author":[{"given":"David S. H.","family":"Bell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,13]]},"reference":[{"issue":"7","key":"1168_CR1","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1177\/000331978403500703","volume":"35","author":"DM Aviado","year":"1984","unstructured":"Aviado DM, Dettelbach HR. Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication. Angiology. 1984;35(7):407\u201317.","journal-title":"Angiology"},{"issue":"2","key":"1168_CR2","first-page":"192","volume":"110","author":"GM Doherty","year":"1991","unstructured":"Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton JA. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery. 1991;110(2):192\u20138.","journal-title":"Surgery"},{"issue":"6","key":"1168_CR3","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s12325-017-0547-2","volume":"34","author":"WX Wen","year":"2017","unstructured":"Wen WX, Lee SY, Siang R, Koh RY. Repurposing pentoxifylline for the treatment of fibrosis: an overview. Adv Ther. 2017;34(6):1245\u201369.","journal-title":"Adv Ther"},{"issue":"Suppl 1","key":"1168_CR4","first-page":"S7","volume":"53","author":"MT De Sanctis","year":"2002","unstructured":"De Sanctis MT, Cesarone MR, Belcaro G, Nicolaides AN, Griffin M, Incandela L, Bucci M, Geroulakos G, Ramaswami G, Vasdekis S, Agus G, Bavera P, Ippolito E. Treatment of intermittent claudication with pentoxifylline: a 12-month, randomized trial\u2013walking distance and microcirculation. Angiology. 2002;53(Suppl 1):S7-12.","journal-title":"Angiology"},{"issue":"6","key":"1168_CR5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/j.1875-9114.1984.tb03380.x","volume":"4","author":"DM Aviado","year":"1984","unstructured":"Aviado DM, Porter JM. Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy. 1984;4(6):297\u2013307.","journal-title":"Pharmacotherapy"},{"key":"1168_CR6","doi-asserted-by":"publisher","unstructured":"Salhiyyah K, Forster R, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev. 2015;9 (9):CD005262. https:\/\/doi.org\/10.1002\/14651858.CD005262.pub3(Update in: Cochrane Database Syst Rev (2020)10:CD005262).","DOI":"10.1002\/14651858.CD005262.pub3"},{"issue":"8","key":"1168_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/00325481.1991.11700966","volume":"89","author":"DS Bell","year":"1991","unstructured":"Bell DS. Lower limb problems in diabetic patients. What are the causes? What are the remedies? Postgrad Med. 1991;89(8):237\u201340 (243\u2013244).","journal-title":"Postgrad Med"},{"issue":"7","key":"1168_CR8","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1177\/000331979404500708","volume":"45","author":"A Chac\u00f3n-Quevedo","year":"1994","unstructured":"Chac\u00f3n-Quevedo A, Eguaras MG, Calleja F, Garcia MA, Roman M, Casares J, Mu\u00f1oz I, Concha M. Comparative evaluation of pentoxifylline, buflomedil, and nifedipine in the treatment of intermittent claudication of the lower limbs. Angiology. 1994;45(7):647\u201353.","journal-title":"Angiology"},{"issue":"6","key":"1168_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/00325481.1982.11716090","volume":"71","author":"RS Clements Jr","year":"1982","unstructured":"Clements RS Jr, Bell DS. Diabetic neuropathy: peripheral and autonomic syndromes. Postgrad Med. 1982;71(6):50\u20132 (55\u201357, 60\u201367).","journal-title":"Postgrad Med"},{"key":"1168_CR10","first-page":"1","volume":"3","author":"RS Clements Jr","year":"1982","unstructured":"Clements RS Jr, Bell DS. Diagnostic, pathogenetic, and therapeutic aspects of diabetic neuropathy. Spec Top Endocrinol Metab. 1982;3:1\u201343.","journal-title":"Spec Top Endocrinol Metab"},{"issue":"3","key":"1168_CR11","first-page":"300","volume":"30","author":"PF Adler","year":"1991","unstructured":"Adler PF. Assessing the effects of pentoxifylline (Trental) on diabetic neurotrophic foot ulcers. J Foot Surg. 1991;30(3):300\u20133.","journal-title":"J Foot Surg"},{"issue":"8","key":"1168_CR12","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1177\/000331979304400805","volume":"44","author":"A Ramani","year":"1993","unstructured":"Ramani A, Kundaje GN, Nayak MN. Hemorheologic approach in the treatment of diabetic foot ulcers. Angiology. 1993;44(8):623\u20136.","journal-title":"Angiology"},{"issue":"1","key":"1168_CR13","first-page":"84","volume":"8","author":"V Rewale","year":"2014","unstructured":"Rewale V, Prabhakar KR, Chitale AM. Pentoxifylline: a new armamentarium in diabetic foot ulcers. J Clin Diagn Res. 2014;8(1):84\u20136.","journal-title":"J Clin Diagn Res"},{"issue":"1\u20133","key":"1168_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ejphar.2012.11.024","volume":"700","author":"S Babaei","year":"2013","unstructured":"Babaei S, Bayat M, Nouruzian M, Bayat M. Pentoxifylline improves cutaneous wound healing in streptozotocin-induced diabetic rats. Eur J Pharmacol. 2013;700(1\u20133):165\u201372.","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"1168_CR15","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/BF00400938","volume":"37","author":"S Tesfaye","year":"1994","unstructured":"Tesfaye S, Malik R, Ward JD. Vascular factors in diabetic neuropathy. Diabetologia. 1994;37(9):847\u201354.","journal-title":"Diabetologia"},{"issue":"3","key":"1168_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/BF00418349","volume":"39","author":"S Tesfaye","year":"1996","unstructured":"Tesfaye S, Malik R, Harris N, Jakubowski JJ, Mody C, Rennie IG, Ward JD. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia. 1996;39(3):329\u201335.","journal-title":"Diabetologia"},{"issue":"4","key":"1168_CR17","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1177\/000331978803900407","volume":"39","author":"RB Kalmansohn","year":"1988","unstructured":"Kalmansohn RB, Kalmansohn RW, Markham CH, Schiff DL. Treatment of diabetic neuropathy with pentoxifylline: case report. Angiology. 1988;39(4):371\u20134.","journal-title":"Angiology"},{"issue":"4","key":"1168_CR18","doi-asserted-by":"publisher","first-page":"600","DOI":"10.7326\/0003-4819-107-4-600_2","volume":"107","author":"KL Cohen","year":"1987","unstructured":"Cohen KL, Harris S. Pentoxifylline and diabetic neuropathy. Ann Intern Med. 1987;107(4):600\u20131.","journal-title":"Ann Intern Med"},{"issue":"9","key":"1168_CR19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1177\/000331979104200908","volume":"42","author":"SM Cohen","year":"1991","unstructured":"Cohen SM, Mathews T. Pentoxifylline in the treatment of distal diabetic neuropathy. Angiology. 1991;42(9):741\u20136.","journal-title":"Angiology"},{"issue":"10","key":"1168_CR20","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.2337\/diacare.13.10.1074","volume":"13","author":"KL Cohen","year":"1990","unstructured":"Cohen KL, Lucibello FE, Chomiak M. Lack of effect of clonidine and pentoxifylline in short-term therapy of diabetic peripheral neuropathy. Diabetes Care. 1990;13(10):1074\u20137.","journal-title":"Diabetes Care"},{"issue":"5","key":"1168_CR21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S1056-8727(96)00077-3","volume":"11","author":"Y Lee","year":"1997","unstructured":"Lee Y, Robinson M, Wong N, Chan E, Charles MA. The effect of pentoxifylline on current perception thresholds in patients with diabetic sensory neuropathy. J Diabetes Complicat. 1997;11(5):274\u20138.","journal-title":"J Diabetes Complicat"},{"key":"1168_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4103\/jrms.JRMS_115_18","volume":"24","author":"F Hosseini","year":"2019","unstructured":"Hosseini F, Mohammadbeigi A, Aghaali M, Borujerdi R, Parham M. Effect of pentoxifylline on diabetic distal polyneuropathy in type 2 diabetic patients: a randomized trial. J Res Med Sci. 2019;24:89.","journal-title":"J Res Med Sci"},{"issue":"7","key":"1168_CR23","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.2337\/dc09-1098","volume":"33","author":"ME Molitch","year":"2010","unstructured":"Molitch ME, Steffes M, Sun W, Rutledge B, Cleary P, de Boer IH, Zinman B, Lachin J, Epidemiology of Diabetes Interventions and Complications Study Group. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care. 2010;33(7):1536\u201343.","journal-title":"Diabetes Care"},{"issue":"2","key":"1168_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1053\/j.ajkd.2009.04.029","volume":"54","author":"AS Levey","year":"2009","unstructured":"Levey AS, Cattran D, Friedman A, Miller WG, Sedor J, Tuttle K, Kasiske B, Hostetter T. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2009;54(2):205\u201326.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1168_CR25","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/ndt\/gfh040","volume":"19","author":"I Pint\u00e9r","year":"2004","unstructured":"Pint\u00e9r I, M\u00e1tyus J, Cz\u00e9g\u00e1ny Z, Hars\u00e1nyi J, Homoki M, Kassai M, Kiss E, Kiss I, Lad\u00e1nyi E, Locsey L, Major L, Misz M, Nagy L, Polner K, R\u00e9dl J, Solt I, Tichy B, T\u00f6r\u00f6k M, Varga G, Wagner G, W\u00f3rum I, Zsoldos B, P\u00f3t\u00f3 L, D\u00e9rczy K, Wittmann I, Nagy J. Analgesic nephropathy in Hungary: the HANS study. Nephrol Dial Transplant. 2004;19(4):840\u20133.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"1168_CR26","doi-asserted-by":"publisher","first-page":"969","DOI":"10.5301\/jn.5000077","volume":"25","author":"M Goicoechea","year":"2012","unstructured":"Goicoechea M, de Vinuesa SG, Quiroga B, Verdalles U, Barraca D, Yuste C, Panizo N, Verde E, Mu\u00f1oz MA, Lu\u00f1o J. Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. J Nephrol. 2012;25(6):969\u201375.","journal-title":"J Nephrol"},{"issue":"3","key":"1168_CR27","doi-asserted-by":"publisher","first-page":"c73","DOI":"10.1159\/000083417","volume":"99","author":"A Aminorroaya","year":"2005","unstructured":"Aminorroaya A, Janghorbani M, Rezvanian H, Aminian T, Gharavi M, Amini M. Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus. Nephron Clin Pract. 2005;99(3):c73\u20137.","journal-title":"Nephron Clin Pract"},{"issue":"7","key":"1168_CR28","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1681\/ASN.2005010001","volume":"16","author":"JF Navarro","year":"2005","unstructured":"Navarro JF, Mora C, Muros M, Garc\u00eda J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol. 2005;16(7):2119\u201326.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1168_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.5414\/CNP64091","volume":"64","author":"M Rodr\u00edguez-Mor\u00e1n","year":"2005","unstructured":"Rodr\u00edguez-Mor\u00e1n M, Guerrero-Romero F. Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients\u2013a randomized, equivalent trial. Clin Nephrol. 2005;64(2):91\u20137.","journal-title":"Clin Nephrol"},{"key":"1168_CR30","doi-asserted-by":"publisher","first-page":"259592","DOI":"10.1155\/2015\/259592","volume":"2015","author":"S Shahidi","year":"2015","unstructured":"Shahidi S, Hoseinbalam M, Iraj B, Akbari M. Effect of pentoxifylline on microalbuminuria in diabetic patients: a randomized controlled trial. Int J Nephrol. 2015;2015:259592.","journal-title":"Int J Nephrol"},{"issue":"3","key":"1168_CR31","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1053\/j.ajkd.2008.01.025","volume":"52","author":"BB McCormick","year":"2008","unstructured":"McCormick BB, Sydor A, Akbari A, Fergusson D, Doucette S, Knoll G. The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis. 2008;52(3):454\u201363.","journal-title":"Am J Kidney Dis"},{"key":"1168_CR32","first-page":"CD006800","volume":"2","author":"D Shan","year":"2012","unstructured":"Shan D, Wu HM, Yuan QY, Li J, Zhou RL, Liu GJ. Pentoxifylline for diabetic kidney disease. Cochrane Database Syst Rev. 2012;2:CD006800.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1168_CR33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jfma.2014.01.002","volume":"113","author":"PM Chen","year":"2014","unstructured":"Chen PM, Lai TS, Chen PY, Lai CF, Wu V, Chiang WC, Chen YM, Wu KD, Tsai TJ. Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease. J Formos Med Assoc. 2014;113(4):219\u201326.","journal-title":"J Formos Med Assoc"},{"issue":"4","key":"1168_CR34","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/cpt.173","volume":"98","author":"PC Wu","year":"2015","unstructured":"Wu PC, Wu CJ, Lin CJ, Pan CF, Chen CY, Huang TM, Wu CH, Lin SL, Chen YM, Chen L, Wu VC, NSARF Group; Kidney Consortium. Pentoxifylline decreases dialysis risk in patients with advanced chronic kidney disease. Clin Pharmacol Ther. 2015;98(4):442\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1168_CR35","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1053\/j.ajkd.2008.11.026","volume":"53","author":"RM Perkins","year":"2009","unstructured":"Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2009;53(4):606\u201316.","journal-title":"Am J Kidney Dis"},{"key":"1168_CR36","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.biopha.2016.10.045","volume":"84","author":"JR Nathan","year":"2016","unstructured":"Nathan JR, Lakshmanan G, Michael FM, Seppan P, Ragunathan M. Expression of adenosine receptors and vegf during angiogenesis and its inhibition by pentoxifylline\u2014a study using zebrafish model. Biomed Pharmacother. 2016;84:1406\u201318.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"1168_CR37","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/0014-4835(92)90009-H","volume":"55","author":"PL Sonkin","year":"1992","unstructured":"Sonkin PL, Freedman SF, Needham D, Rao KM, Hatchell DL. Pentoxifylline modulates deformability, F-actin content, and superoxide anion production of polymorphonuclear leukocytes from diabetic cats. Exp Eye Res. 1992;55(6):831\u20138.","journal-title":"Exp Eye Res"},{"issue":"6","key":"1168_CR38","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S0002-9394(14)73647-5","volume":"115","author":"PL Sonkin","year":"1993","unstructured":"Sonkin PL, Sinclair SH, Hatchell DL. The effect of pentoxifylline on retinal capillary blood flow velocity and whole blood viscosity. Am J Ophthalmol. 1993;115(6):775\u201380.","journal-title":"Am J Ophthalmol"},{"issue":"1\u20132","key":"1168_CR39","first-page":"19","volume":"26","author":"M Baykara","year":"2013","unstructured":"Baykara M, Atabek ME, Eklioglu BS, Kurtoglu S. Pentoxifylline treatment for protecting diabetic retinopaty in children with type 1 diabetes. J Pediatr Endocrinol Metab. 2013;26(1\u20132):19\u201324.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"6","key":"1168_CR40","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1177\/0003319794045006032","volume":"45","author":"J Sebag","year":"1994","unstructured":"Sebag J, Tang M, Brown S, Sadun AA, Charles MA. Effects of pentoxifylline on choroidal blood flow in nonproliferative diabetic retinopathy. Angiology. 1994;45(6):429\u201333.","journal-title":"Angiology"},{"issue":"2","key":"1168_CR41","first-page":"CD006693","volume":"2008","author":"CCL de Jesus","year":"2008","unstructured":"de Jesus CCL, Atallah AN, Valente O, Trevisani VFM. Pentoxifylline for diabetic retinopathy. Cochrane Database Syst Rev. 2008;2008(2):CD006693.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1168_CR42","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000115765","volume":"24","author":"E Herskovits","year":"1985","unstructured":"Herskovits E, Famulari A, Tamaroff L, Gonzalez AM, V\u00e1zquez A, Dominguez R, Fraiman H, Vila J. Preventive treatment of cerebral transient ischemia: comparative randomized trial of pentoxifylline versus conventional antiaggregants. Eur Neurol. 1985;24(1):73\u201381.","journal-title":"Eur Neurol"},{"key":"1168_CR43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1600-0404.1989.tb01808.x","volume":"127","author":"E Herskovits","year":"1989","unstructured":"Herskovits E, Famulari A, Tamaroff L, Gonzalez AM, Vzquez A, Dominguez R, Fraiman H, Vila J, Benjamin V, Matera V. Comparative study of pentoxifylline vs antiaggregants in patients with transient ischaemic attacks. Acta Neurol Scand Suppl. 1989;127:31\u20135.","journal-title":"Acta Neurol Scand Suppl"},{"key":"1168_CR44","doi-asserted-by":"crossref","unstructured":"Bath PM, Bath-Hextall FJ. Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke. Cochrane Database Syst Rev. 2004;(3):CD000162.","DOI":"10.1002\/14651858.CD000162.pub2"},{"issue":"1","key":"1168_CR45","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/00002093-200301000-00006","volume":"17","author":"MC Sha","year":"2003","unstructured":"Sha MC, Callahan CM. The efficacy of pentoxifylline in the treatment of vascular dementia: a systematic review. Alzheimer Dis Assoc Disord. 2003;17(1):46\u201354.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"6","key":"1168_CR46","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/SHK.0000000000000044","volume":"40","author":"ZV Schofield","year":"2013","unstructured":"Schofield ZV, Woodruff TM, Halai R, Wu MC, Cooper MA. Neutrophils\u2014a key component of ischemia-reperfusion injury. Shock. 2013;40(6):463\u201370.","journal-title":"Shock"},{"issue":"7","key":"1168_CR47","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1185\/03007998509109621","volume":"9","author":"A Hartmann","year":"1985","unstructured":"Hartmann A. Comparative randomized study of cerebral blood flow after long-term administration of pentoxifylline and co-dergocrine mesylate in patients with chronic cerebrovascular disease. Curr Med Res Opin. 1985;9(7):475\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"1168_CR48","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.atherosclerosis.2006.07.034","volume":"192","author":"K Prasad","year":"2007","unstructured":"Prasad K, Lee P. Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism. Atherosclerosis. 2007;192(2):313\u201322.","journal-title":"Atherosclerosis"},{"issue":"11\u201312","key":"1168_CR49","first-page":"945","volume":"24","author":"ME Atabek","year":"2011","unstructured":"Atabek ME, Kurtoglu S, Selver B, Baykara M. Effectiveness of pentoxifylline on the cross-sectional area of intima media thickness and functions of the common carotid artery in adolescents with type 1 diabetes. J Pediatr Endocrinol Metab. 2011;24(11\u201312):945\u201351.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"1","key":"1168_CR50","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.atherosclerosis.2006.11.032","volume":"196","author":"JL Fernandes","year":"2008","unstructured":"Fernandes JL, de Oliveira RTD, Mamoni RL, Coelho OR, Nicolau JC, Blotta MHSL, Serrano CV Jr. Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease\u2013a randomized placebo-controlled study. Atherosclerosis. 2008;196(1):434\u201342.","journal-title":"Atherosclerosis"},{"issue":"4","key":"1168_CR51","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/1755-5922.12076","volume":"32","author":"S Champion","year":"2014","unstructured":"Champion S, Lapidus N, Cheri\u00e9 G, Spagnoli V, Oliary J, Solal AC. Pentoxifylline in heart failure: a meta-analysis of clinical trials. Cardiovasc Ther. 2014;32(4):159\u201362.","journal-title":"Cardiovasc Ther"},{"issue":"1","key":"1168_CR52","doi-asserted-by":"publisher","first-page":"e000365","DOI":"10.1136\/openhrt-2015-000365","volume":"3","author":"MF McCarty","year":"2016","unstructured":"McCarty MF, O\u2019Keefe JH, DiNicolantonio JJ. Pentoxifylline for vascular health: a brief review of the literature. Open Heart. 2016;3(1):e000365.","journal-title":"Open Heart"},{"issue":"3","key":"1168_CR53","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/hep.24483","volume":"54","author":"R Lomonaco","year":"2011","unstructured":"Lomonaco R, Ortiz-Lopez C, Orsak B, Finch J, Webb A, Bril F, Louden C, Tio F, Cusi K. Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepatology. 2011;54(3):837\u201345.","journal-title":"Hepatology"},{"issue":"5","key":"1168_CR54","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/j.1478-3231.2011.02482.x","volume":"31","author":"NC Leite","year":"2011","unstructured":"Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, Salles GF. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int. 2011;31(5):700\u20136.","journal-title":"Liver Int"},{"issue":"2","key":"1168_CR55","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389\u201397.","journal-title":"Gastroenterology"},{"issue":"12","key":"1168_CR56","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1016\/j.cgh.2015.07.029","volume":"13","author":"A Ahmed","year":"2015","unstructured":"Ahmed A, Wong RJ, Harrison SA. Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol. 2015;13(12):2062\u201370.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"1168_CR57","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s10620-016-4083-8","volume":"61","author":"KE Corey","year":"2016","unstructured":"Corey KE, Rinella ME. Medical and surgical treatment options for nonalcoholic steatohepatitis. Dig Dis Sci. 2016;61(5):1387\u201397.","journal-title":"Dig Dis Sci"},{"issue":"4","key":"1168_CR58","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/hep.25778","volume":"56","author":"CO Zein","year":"2012","unstructured":"Zein CO, Lopez R, Fu X, Kirwan JP, Yerian LM, McCullough AJ, Hazen SL, Feldstein AE. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology. 2012;56(4):1291\u20139.","journal-title":"Hepatology"},{"issue":"3","key":"1168_CR59","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1665-2681(19)31539-X","volume":"10","author":"LB Van Wagner","year":"2011","unstructured":"Van Wagner LB, Koppe SW, Brunt EM, Gottstein J, Gardikiotes K, Green RM, Rinella ME. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol. 2011;10(3):277\u201386.","journal-title":"Ann Hepatol"},{"issue":"3","key":"1168_CR60","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1515\/jtim-2017-0021","volume":"5","author":"S Alam","year":"2017","unstructured":"Alam S, Nazmul Hasan S, Mustafa G, Alam M, Kamal M, Ahmad N. Effect of pentoxifylline on histological activity and fibrosis of nonalcoholic steatohepatitis patients: a one year randomized control trial. J Transl Int Med. 2017;5(3):155\u201363.","journal-title":"J Transl Int Med"},{"issue":"4","key":"1168_CR61","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jceh.2012.10.010","volume":"2","author":"BC Sharma","year":"2012","unstructured":"Sharma BC, Kumar A, Garg V, Reddy RS, Sakhuja P, Sarin SK. A randomized controlled trial comparing efficacy of pentoxifylline and pioglitazone on metabolic factors and liver histology in patients with non-alcoholic steatohepatitis. J Clin Exp Hepatol. 2012;2(4):333\u20137.","journal-title":"J Clin Exp Hepatol"},{"issue":"1","key":"1168_CR62","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1006\/jaut.2000.0456","volume":"16","author":"S Stosi\u0107-Grujici\u0107","year":"2001","unstructured":"Stosi\u0107-Grujici\u0107 S, Maksimovi\u0107 D, Badovinac V, Samardzi\u0107 T, Trajkovi\u0107 V, Luki\u0107 M, Mostarica SM. Antidiabetogenic effect of pentoxifylline is associated with systemic and target tissue modulation of cytokines and nitric oxide production. J Autoimmun. 2001;16(1):47\u201358.","journal-title":"J Autoimmun"},{"key":"1168_CR63","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/2193-1801-3-283","volume":"3","author":"FA Garcia","year":"2014","unstructured":"Garcia FA, Pinto SF, Cavalcante AF, Lucetti LT, Menezes SM, Felipe CF, Alves AP, Brito GA, Cerqueira GS, Viana GS. Pentoxifylline decreases glycemia levels and TNF-alpha, iNOS and COX-2 expressions in diabetic rat pancreas. Springerplus. 2014;3:283.","journal-title":"Springerplus"},{"key":"1168_CR64","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12950-015-0080-5","volume":"12","author":"FA Garcia","year":"2015","unstructured":"Garcia FA, Rebou\u00e7as JF, Balbino TQ, da Silva TG, de Carvalho-J\u00fanior CH, Cerqueira GS, Brito GA, Viana GS. Pentoxifylline reduces the inflammatory process in diabetic rats: relationship with decreases of pro-inflammatory cytokines and inducible nitric oxide synthase. J Inflamm (Lond). 2015;12:33.","journal-title":"J Inflamm (Lond)"},{"issue":"6","key":"1168_CR65","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1152\/jappl.1994.77.6.2767","volume":"77","author":"EP Corssmit","year":"1985","unstructured":"Corssmit EP, Romijn JA, Endert E, Sauerwein HP. Pentoxifylline inhibits basal glucose production in humans. J Appl Physiol. 1985;77(6):2767\u201372.","journal-title":"J Appl Physiol"},{"issue":"3","key":"1168_CR66","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/BF02732036","volume":"24","author":"S Raptis","year":"1987","unstructured":"Raptis S, Mitrakou A, Hadjidakis D, Diamantopoulos E, Anastasiou C, Fountas A, M\u00fcller R. 24-h blood glucose pattern in type I and type II diabetics after oral treatment with pentoxifylline as assessed by artificial endocrine pancreas. Acta Diabetol Lat. 1987;24(3):181\u201392.","journal-title":"Acta Diabetol Lat"},{"key":"1168_CR67","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13098-015-0060-1","volume":"7","author":"SJ Han","year":"2015","unstructured":"Han SJ, Kim HJ, Kim DJ, Sheen SS, Chung CH, Ahn CW, Kim SH, Cho YW, Park SW, Kim SK, Kim CS, Kim KW, Lee KW. Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study. Diabetol Metab Syndr. 2015;7:64.","journal-title":"Diabetol Metab Syndr"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-021-01168-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-021-01168-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-021-01168-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T14:44:26Z","timestamp":1675781066000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-021-01168-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,13]]},"references-count":67,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1168"],"URL":"https:\/\/doi.org\/10.1007\/s13300-021-01168-x","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,13]]},"assertion":[{"value":"2 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}